Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report-Reference-Cited by-同舟云学术

Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report

Published:2022-05-26 Issue:13 Volume:13 Page:1994-1997
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Magdelaine Pierre¹,Costantini Adrien¹²,Fabre Lucie³,Giroux‐Leprieur Etienne¹²^ORCID

Affiliation:

1. Department of Respiratory Diseases and Thoracic Oncology APHP – Hopital Ambroise Pare Boulogne‐Billancourt France

2. University Paris‐Saclay, UVSQ, EA 4340 BECCOH Boulogne‐Billancourt France

3. Department of pathology APHP‐Hopital Ambroise Pare Boulogne‐Billancourt France

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14405

Reference11 articles.

1. Association between immune‐related dermatologic adverse events and efficacy of pembrolizumab in non‐small cell lung cancer patients;Fukuoka T;Pharmazie,2021

2. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

3. Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.

4. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis

5. Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Features and Management of Dermatologic Immune-Related Adverse Events for the Inpatient Dermatologist;Current Dermatology Reports;2023-07-17

2. Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management;American Journal of Clinical Dermatology;2023-05-08

3. Gemcitabine/nivolumab;Reactions Weekly;2022-06